<?xml version="1.0" encoding="UTF-8"?>
<ref id="CR19">
 <label>19.</label>
 <element-citation publication-type="journal">
  <person-group person-group-type="author">
   <name>
    <surname>Lee</surname>
    <given-names>NY</given-names>
   </name>
   <name>
    <surname>Zhang</surname>
    <given-names>Q</given-names>
   </name>
   <name>
    <surname>Pfister</surname>
    <given-names>DG</given-names>
   </name>
   <name>
    <surname>Kim</surname>
    <given-names>J</given-names>
   </name>
   <name>
    <surname>Garden</surname>
    <given-names>AS</given-names>
   </name>
   <name>
    <surname>Mechalakos</surname>
    <given-names>J</given-names>
   </name>
   <etal/>
  </person-group>
  <article-title>Addition of bevacizumab to standard chemoradiation for locoregionally advanced nasopharyngeal carcinoma (RTOG 0615): a phase 2 multi-institutional trial</article-title>
  <source>Lancet Oncol</source>
  <year>2012</year>
  <volume>13</volume>
  <issue>2</issue>
  <fpage>172</fpage>
  <lpage>180</lpage>
  <pub-id pub-id-type="doi">10.1016/S1470-2045(11)70303-5</pub-id>
  <pub-id pub-id-type="pmid">22178121</pub-id>
 </element-citation>
</ref>
